Do You Gain Weight After Stopping Ozempic, Wegovy or Zepbound? What the Trials Show

Yes, for most people a substantial part of the weight comes back after stopping a GLP-1 drug. The randomized withdrawal trials agree on that. They also show two things that get lost in the headlines: people rarely regain all of it within a year, and the average hides a very wide spread between individuals.

This article is educational content and does not constitute medical advice. Decisions about stopping or changing a prescription belong to you and your prescriber.

The short answer

• In the STEP 1 extension, people regained about two-thirds of the weight they had lost on semaglutide within a year of stopping.
• In STEP 4, people switched from semaglutide to placebo regained 6.9% of body weight over 48 weeks, while those who stayed on it kept losing.
• In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of body weight over a year, but most still weighed less than when they started.
• Improvements in blood pressure, blood sugar and cholesterol drifted back along with the weight.
• None of these trials gave participants a plan for the months after stopping. They simply stopped.

What the withdrawal trials found

Three large trials were designed to answer this question directly: they gave everyone the drug, then stopped it for some participants on purpose and followed what happened.

Trial	Drug	Weight lost on the drug	After stopping
STEP 1 extension	Semaglutide 2.4 mg	About 17% over 68 weeks	About two-thirds of the loss regained within a year
STEP 4	Semaglutide 2.4 mg	About 10.6% over 20 weeks	6.9% of body weight regained over 48 weeks on placebo
SURMOUNT-4	Tirzepatide 10 or 15 mg	About 20.9% over 36 weeks	14% of body weight regained over 52 weeks on placebo

STEP 1 extension (semaglutide)

STEP 1 was the trial that got semaglutide 2.4 mg (Wegovy) approved for weight management. When the 68-week treatment period ended, the drug was stopped and a subset of participants was followed for another year with no drug and no structured lifestyle program. By the end of that year they had regained roughly two-thirds of what they had lost, leaving them about 5–6% below their starting weight on average. Blood pressure, HbA1c and cholesterol, which had all improved on treatment, moved back toward baseline. You can read the main trial results in our STEP 1 summary.

STEP 4 (semaglutide)

STEP 4 is the cleaner experiment. Everyone took semaglutide for 20 weeks and lost about 10.6% of body weight, then participants were randomized: two-thirds continued, one-third switched to a placebo injection without knowing it. Over the next 48 weeks the continuing group lost a further 7.9%, while the placebo group regained 6.9% of body weight. The two groups began to separate soon after the switch.

SURMOUNT-4 (tirzepatide)

SURMOUNT-4 ran the same design with tirzepatide (Zepbound, Mounjaro). After 36 weeks at the highest tolerated dose, participants had lost about 20.9% of body weight. Those who continued lost a further 5.5% over the following year. Those switched to placebo regained 14% of body weight, yet on average still ended up around 10% lighter than when they began. The full program is covered in our SURMOUNT summary.

How fast does the weight come back?

Regain does not start the day after the last injection. Semaglutide has a half-life of about a week and tirzepatide about five days, so both take four to five weeks to clear, and appetite tends to return gradually over that window.

In the trials, regain was fastest in the first few months after stopping and slowed after that, though it had not clearly levelled off by the end of follow-up. In practice that makes the first three months after the last dose the period that matters most, which is why a structured off-ramp front-loads the work into those weeks.

Why the weight comes back

GLP-1 drugs do not reset body weight. They hold appetite down and fullness up for as long as they are in your system. Three things then work against you when they clear:

• Appetite biology returns. After weight loss, hunger hormones and the brain's drive to eat push toward regaining the lost weight. The drug was holding that drive back; stopping removes the brake. The return of "food noise" is the most commonly described change, and our food noise explainer covers the neuroscience.
• Energy needs are lower. A smaller body burns less energy, and any muscle lost along the way lowers it further. Eating the way you did before the drug now produces a surplus.
• Habits were built on a suppressed appetite. Small portions were easy because the drug made them easy. Without a plan for real hunger, portion sizes and snacking creep back.

Muscle is the part most within your control. Trial body-composition data suggest a meaningful share of GLP-1 weight loss can be lean tissue, which is why protein and resistance training matter before and after stopping. Our muscle mass guide covers the data.

Who regains less?

The honest answer is that the withdrawal trials were not designed to find out, and the individual results varied widely: some people regained almost nothing, others more than they had lost.

The best clue so far comes from a Danish trial of liraglutide, an older GLP-1 drug. People who had combined the drug with a structured exercise program kept more of their weight loss a year after stopping than those who had taken the drug alone. That fits what long-term weight maintainers report outside of drug trials: regular physical activity and weighing themselves at least once a week are among the most consistent habits.

Tapering is often suggested as a way to reduce regain. It is a reasonable approach, and it slows the return of appetite, but it has not yet been tested against stopping outright in a randomized trial. The evidence so far is observational.

What you can do about it

If you are planning to stop, the four things within your control are:

1. Plan the stop with your prescriber. Decide whether to step down, move to a lower maintenance dose, or stop outright, and agree what happens if the weight comes back. The Off-Ramp Checklist lists the questions to ask.
2. Protect your muscle. Eat 1.2–1.6 g of protein per kg of body weight a day and lift weights three times a week.
3. Prepare for hunger. Protein- and fiber-first meals, a plan for evenings and weekends, and enough sleep. See what to eat after stopping a GLP-1.
4. Watch the trend. Track a 7-day average weight and agree in advance on the number that means "call the prescriber", for example 5% above your stop weight.

The GLP-1 off-ramp guide puts these into a 16-week plan, and the Taper Planner has step-down schedules from every dose of Zepbound, Wegovy, Ozempic and Mounjaro.

Is staying on the drug the better option?

For many people the evidence points toward long-term treatment, in the same way blood pressure or cholesterol medicines work only while you take them. That does not have to mean the top dose forever: some people hold their weight on a lower maintenance dose, which also lowers the cost. Whether that is right for you depends on why you want to stop, what your coverage allows, and your other health conditions, which is a conversation for your prescriber.

Common questions

Will I gain all the weight back after stopping Ozempic?

Most people in the semaglutide trials regained a large share, about two-thirds of the loss within a year in the STEP 1 extension, but not all of it on average. Individual results ranged widely.

How long after stopping Wegovy or Ozempic does weight come back?

Appetite usually starts to return within a few weeks of the last dose as semaglutide clears, and the trials show regain was fastest over the first few months.

Does tapering off prevent weight gain?

Not proven. Tapering slows the return of appetite and can show whether a lower dose holds your weight, but no randomized trial has yet shown that it reduces regain compared with stopping outright.

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider before making decisions about medications.